Full data are being presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium on Friday, December 8. Kadcyla is approved ...
News
- Genentech's Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival ... - BioSpace
- Intensity Therapeutics rockets on positive INT230-6 data - The Pharma Letter
... San Antonio Breast Cancer Symposium. The trial showed that: INT230-6 ... BiotechnologyBreast cancerConferencesDrug TrialINT230-6Intensity ...
- Bluebird bio's sickle-cell disease treatment nets FDA approval - Boston Business Journal
San Antonio · San Francisco · Seattle · Silicon Valley · St. Louis · Tampa Bay ... Biotech led by ex-Novartis exec brings in $90M for cancer drugs.
- Neoadjuvant Treatment Combos Face Off in HER2+ Breast Cancer
These findings, from the APTneo trial (ClinicalTrials.gov Identifier: NCT03595592), were presented at the San Antonio Breast Cancer Symposium 2023.
- Pregnancy After Breast Cancer Treatment Is Not Contraindicated in BRCA Carriers
... San Antonio Breast Cancer Symposium 2023. The study results provide ... Disclosures: Some study authors declared affiliations with biotech, ...